<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002804</url>
  </required_header>
  <id_info>
    <org_study_id>9553</org_study_id>
    <secondary_id>POG-9553</secondary_id>
    <secondary_id>CDR0000064905</secondary_id>
    <secondary_id>COG-P9953</secondary_id>
    <nct_id>NCT00002804</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma</brief_title>
  <official_title>Phase II Study of Neoadjuvant Vincristine, Ifosfamide, Doxorubicin, and AND G-CSF in Children With Advanced Stage Non-Rhabdomyosarcoma Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, surgery, and
      radiation therapy in treating children who have advanced soft tissue sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the response to vincristine/ifosfamide/doxorubicin (VID) with
      granulocyte colony-stimulating factor support in children with newly diagnosed, inoperable or
      metastatic non-rhabdomyosarcoma soft tissue sarcomas. II. Estimate the 2-year and event-free
      survival rates in children treated with VID plus radiotherapy and/or surgery. III. Establish
      a bank of frozen tumor and peripheral blood tissue for use in further molecular studies.

      OUTLINE: The following acronyms are used: DOX Doxorubicin, NSC-123127 G-CSF Granulocyte
      Colony-Stimulating Factor (Amgen), NSC-614629 IFF Ifosfamide, NSC-109724 Mesna Mercaptoethane
      sulfonate, NSC-113891 VCR Vincristine, NSC-67574 VID VCR/IFF/DOX Induction: 3-Drug
      Combination Chemotherapy. VID. Local Control: Surgery and/or Radiotherapy plus 3-Drug
      Combination Chemotherapy. Excision of the primary tumor and pulmonary metastases; and/or
      irradiation of the primary tumor and pulmonary metastases using x-rays or Co60 beam energies
      of at least 4 MV (electrons or iridium-192 implant allowed for boost); plus VID.
      Continuation: 3-Drug Combination Chemotherapy. VID.

      PROJECTED ACCRUAL: A total of 40 patients will be entered over 2.7 years if there are at
      least 7 responses in the first 20 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1996</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">June 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the response rate to the combination of vincristine, ifosfamide, and doxorubicin (VID), with G-CSF support</measure>
    <description>To estimate the response rate to the combination of vincristine, ifosfamide, and doxorubicin (VID), with G-CSF support, in children with newly diagnosed inoperable or metastatic non-rhabdomyosarcoma soft tissue sarcomas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <description>To estimate the 2-year survival and event-free survival of children treated with VID in combination with radiotherapy and/or surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish a bank of frozen tissue (tumor and peripheral blood)</measure>
    <description>To establish a bank of frozen tissue (tumor and peripheral blood) for use in further molecular studies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
    <other_name>Granulocyte-Colony Stimulating Factor</other_name>
    <other_name>Neupogen</other_name>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>NSC#123127</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
    <other_name>Isophosphamide</other_name>
    <other_name>IFEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
    <other_name>Sodium 2-Mercaptoethane Sulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>Urimetexan</other_name>
    <other_name>NSC#113891</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC#67574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET cobalt-60 gamma ray therapy</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET electron therapy</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
    <arm_group_label>Chemotherapy Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Biopsy proven non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)
        Evaluable residual tumor after initial biopsy or excision required Registration required
        within 42 days of definitive diagnosis Grade II/III, unresectable or metastatic disease The
        following histologies exclude: Angiofibroma of the nasopharynx Mesothelioma Desmoid tumor
        Peripheral neuroepithelioma Desmoplastic small cell tumor Rhabdomyosarcoma Extraosseous
        Ewing's sarcoma Undifferentiated sarcoma Kaposi's sarcoma Grade 1 NRSTS, including:
        Angiomatoid malignant fibrous histiocytoma Dermatofibrosarcoma protuberans Myxoid and
        well-differentiated liposarcoma Well-differentiated and infantile hemangiopericytoma
        Well-differentiated malignant peripheral nerve sheath tumor

        PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Hematopoietic:
        Not specified Hepatic: Not specified Renal: Creatinine normal for age No hydronephrosis
        Cardiovascular: Shortening fraction greater than 28% Other: No HIV infection Not pregnant
        or nursing Effective contraception required of fertile women

        PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy No prior nephrectomy
        (surgical correction of hydronephrosis allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto S. Pappo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Pediatric Cancer and Blood Disorders Center</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <zip>78236-5300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center, University of Virginia HSC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico School of Medicine Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Pediatrie</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2004</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

